Scientific Advisory Board
Dr. James Watson
As a pioneer in early biomedical research, Watson co-discovered the structure of DNA in 1953 with Francis Crick and Rosalind Franklin. The three were awarded the 1962 Nobel Prize in Physiology or Medicine “for their discoveries concerning the molecular structure of nucleic acids and its significance for information transfer in living material”. Subsequently, Watson undertook instrumental work with the National Institutes of Health and helped to establish the Human Genome Project. For almost 40 years, he also served as Director and President of Cold Spring Harbor Laboratory where helped define the organization’s mission and direction.
Dr. Jeffrey Cummings
Dr. Cummings is currently Professor of Neurotherapeutics and Drug Development in the Neurological Institute, Cleveland Clinic; he is Director of the Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada and Cleveland, Ohio. His previous positions included several prominent positions at the UCLA. He attended medical school at the University of Wyoming, Seattle and completed his internship at the Hartford Hospital in Hartford, Connecticut. He’s received several awards, including the Distinguished Scientist Award from the American Association of Geriatric Psychiatry and the Ronald and Nancy Reagan Research Award from the National Alzheimer’s Association.
Dr. Steve Arnold
Dr. Arnold is Translational Neurology Head of the Interdisciplinary Brain Center at Massachusetts General Hospital, Harvard Medical School. Board certified in both neurology and psychiatry, he attended medical school at Boston University and completed his residency training in Psychiatry at the New York State Psychiatric Institute / Columbia Presbyterian Medical Center in New York and Neurology at the University of Iowa Hospitals and Clinics in Iowa City. He’s previously served as a faculty member and Director at the University of Pennsylvania’s Penn Memory Center as well as Associate Director at the Institute of Aging. He’s authored more than 250 scientific articles, reviews and chapters.
Dr. Nick Fox
Nick Fox currently holds the position of Director of the Dementia Research Centre at the University College London and is also Professor of Neurology and MRC Senior Clinical Fellow at the Institute of Neurology. In addition, he serves as a Consultant Neurologist at the National Hospital for Neurology and Neurosurgery as well as co-chairs the Research Advisory Committee of the Alzheimer’s Society and is a member of Alzheimer’s Research UK’s Scientific Advisory Board. His first degree was in Physics and Physiology from Cambridge and he graduated with honors in medicine from the University of London and subsequently specialized in cognitive neurology. His research publications focus on the early detection, differential diagnosis and monitoring of progression in cognitive disorders and neurodegenerative dementias.
Dr. Brad Hyman
Dr. Hyman is Professor of Neurology at Harvard Medical School and serves as the Alzheimer’s Unit Director at the MassGeneral Institute for Neurodegenerative Disease as well as Director at Massachusetts Alzheimer’s Disease Research Center. His research focuses on the neural system failure that underlies cognitive loss in Alzheimer’s, and how genetics impacts pathophysiology. He was educated at Northwestern (BA) and the University of Iowa (PhD; MD). He’s received multiple awards and recognitions including the Metropolitan Life Award, the Potamkin Prize, a National Institute on Aging MERIT award, and an Alzheimer Association Pioneer Award.
Dr. Wayne Koff
Dr. Koff is President and Chief Executive Officer (CEO) of the Human Vaccines Project, a nonprofit public private partnership with the mission to accelerate the development of vaccines and immunotherapies for major diseases by decoding the human immune system. Previously, he worked for 17 years at the International AIDS Vaccines Initiative (IAVI) in several roles, including as its Chief Scientific Officer. He also serves as an adjunct professor in the Department of Microbiology at the State University of New York, Stony Brook and has published more than 100 scientific papers and edited seven books on vaccine development. He received his PhD from the Baylor College of Medicine. He has been honored twice by the United States Department of Health and Human Services with the Special Act of Service Award for developing innovative strategies to accelerate the development of AIDS vaccines.
Dr. Eric Reiman
Dr. Reiman is Executive Director of the Banner Alzheimer’s Institute and Chief Executive Officer for Banner Research. He is also Professor of Psychiatry at the University of Arizona, University Professor of Neuroscience at Arizona State University, Clinical Director of Neurogenomics at the Translational Genomics Research Institute (TGen), and Director of the Arizona Alzheimer’s Consortium. Dr. Reiman earned his undergraduate and medical degrees at Duke University and completed residencies at Duke University and Washington University in St. Louis. He has authored over 300 publications, been a principal investigator of several large NIH grants, and has received the Potamkin Prize.
Currently, Mr. Sistemans is the Chairman of the Advisory Council for Science and Technology Policy to the Prime Minister, the Netherlands. He serves on the boards of numerous private and public organizations in the Netherlands. He has been a Supervisory Board Member of the University in Enschede the Netherlandss and the Maastricht School of Management. He was the CEO of Origin B.V., an information technology company in the Netherlands from 1999 to 2001. From 1994 to 1999, Mr. Sistermans served as the Executive Vice President of Akzo Nobel responsible for Strategy and Technology.
H.E. Dr. Thomas Zeltner, MD, LLM
Thomas Zeltner, MD, is an international expert leader in public health and health system development and former Secretary of Health of Switzerland and Federal Department of Home Affairs. He is a 2010 Fellow of the Advanced Leadership Initiative of Harvard University. He is co-founder of the Global Patient Safety Forum, a convening organization of the world’s leading patient safety organizations, and a Managing Editor of the Journal of Patient Safety. He advises international organizations and national governments in health policies and health policy reforms. He has served as Special Envoy in financing for WHO. In this capacity, he advised the Director General of WHO on the identification of an improved financing framework for the Organization. He is a member of the Global Agenda Council on Digital Health of the World Economic Forum (WEF). Dr. Zeltner is president of Blood Transfusion CRS Switzerland, the organization in charge of securing Switzerland’s provision with blood and blood products. He is a board member of the Swiss Academies of Arts and Sciences and President of Science-et-Cite:copyright:. Since 1992, he has been Professor of Public Health at the University of Bern, Switzerland. From 1991 to 2009, Dr. Zeltner was the Director-General of the Federal Office of Public Health of Switzerland, the National Health and Public Health Authority and Secretary of State for Health. In this function he was a key actor in Swiss health policy and represented Switzerland in many international health organizations.
He has served as the Assistant Editor for Global Programmes for the Journal of Patient Safety and is a subject matter expert on global public health issues for the Journal. He graduated with an MD and a master’s degree in law from the University of Bern. He holds a specialist degree in human pathology and forensic medicine.
Dr. Dietrich Stephan, PhD
Dietrich Stephan is the Chairman of the Department of the Department of Human Genetics at the University of Pittsburgh, and Associate Director of the Institute for Personalized Medicine of Pitt/UPMC where he leads the efforts in population genetics and translational acceleration. Prior to coming to Pittsburgh in 2013, he was founder, president and CEO of Silicon Valley Biosystems (SV Bio). Prior to founding SV Bio, Dr. Stephan was executive director of the Gene Partnership at Children’s Hospital Boston-Harvard Medical School – the nation’s No. 1-ranked pediatric hospital – where he worked to re-architect their care delivery model to bring modern genomic tools and strategies to bear to improve outcomes. In 2005, Dr. Stephan founded Navigenics Inc., later acquired by Life Technologies in 2012. Prior to founding Navigenics, Dr. Stephan served on the leadership team at the Translational Genomics Research Institute (TGen) as professor and chairman of the Neurogenomics Department and deputy director for Discovery Research of the institute overall, where he oversaw research and development. He has founded several additional companies in the San Francisco Bay Area, including Aueon (cancer diagnostics), Amnestix (a pharmaceutical company developing cognitive enhancers acquired in 2007) and DiaVacs (an immunotherapy company focused on a cure for juvenile diabetes).
Dr. Campbell Murray, MD, MBA, MPH
Dr. Campbell Murray is a Managing Director of Novartis Venture Fund in Cambridge, MA, USA. Prior to joining he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects. Campbell is a New Zealand-trained physician and worked as a Medical House Officer at Auckland Hospital. He is a Kauffman Fellow and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government, where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell serves on the boards of Aerpio, BioNano Genomics, Euthymics, Galera, ImaginAb and Neurovance.
Dr. Jeremy Friese, MD
Dr. Friese is an interventional radiologist at Mayo Clinic in Rochester, Minnesota. His clinical and research focus includes minimally invasive vascular disease and cancer. He serves as Medical Director for New Ventures and Business Development in the Center for Individualized Medicine and as Associate Chair of Finance in the Department of Radiology. He is past chair of Novation’s imaging council and currently sits on the cardiovascular council. Dr. Friese is co-founder of Evidentia Health (a seed-stage HIT company), an active angel investor, and board member for SV Biosystems, Inc. He earned an M.D. from Mayo Medical School and an M.B.A. from Harvard Business School where he collaborated with Professors Clay Christensen and Michael Porter.